Total Payments
$50,979
2024 Payments
$1,743
Companies
52
Transactions
557
Medicare Patients
8,199
Medicare Billing
$3.2M
Payment Breakdown by Category
Research$38,182 (74.9%)
Food & Beverage$8,187 (16.1%)
Consulting$4,400 (8.6%)
Education$210.34 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38,182 | 18 | 74.9% |
| Food and Beverage | $8,187 | 527 | 16.1% |
| Consulting Fee | $4,400 | 4 | 8.6% |
| Education | $210.34 | 8 | 0.4% |
Payments by Type
Research
$38,182
18 transactions
General
$12,797
539 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $38,093 | 22 | $0 (2024) |
| Merck Sharp & Dohme LLC | $4,981 | 57 | $0 (2023) |
| PFIZER INC. | $1,052 | 87 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $793.93 | 62 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $583.81 | 33 | $0 (2024) |
| Celgene Corporation | $569.39 | 34 | $0 (2024) |
| Amgen Inc. | $465.94 | 32 | $0 (2023) |
| Genentech USA, Inc. | $353.68 | 19 | $0 (2024) |
| ABBVIE INC. | $339.20 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $328.39 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,743 | 94 | Novartis Pharmaceuticals Corporation ($275.95) |
| 2023 | $6,163 | 91 | Merck Sharp & Dohme LLC ($4,400) |
| 2022 | $619.76 | 35 | Merck Sharp & Dohme LLC ($63.13) |
| 2021 | $94.62 | 7 | Myovant Sciences Inc. ($34.82) |
| 2020 | $269.39 | 19 | Merck Sharp & Dohme Corporation ($63.83) |
| 2019 | $16,071 | 96 | Takeda Pharmaceuticals U.S.A., Inc. ($14,750) |
| 2018 | $24,963 | 132 | Takeda Pharmaceuticals U.S.A., Inc. ($23,275) |
| 2017 | $1,055 | 83 | E.R. Squibb & Sons, L.L.C. ($164.20) |
All Payment Transactions
557 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.31 | General |
| Category: Hematology | ||||||
| 12/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.15 | General |
| Category: Hematology | ||||||
| 11/22/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: BioOncology | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.20 | General |
| 10/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $30.21 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.15 | General |
| Category: Hematology | ||||||
| 10/21/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: DESMOID TUMORS | ||||||
| 10/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.94 | General |
| Category: Hematology | ||||||
| 10/15/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $11.94 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $2.90 | General |
| Category: Oncology | ||||||
| 09/27/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: BioOncology | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI, DARZALEX | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.68 | General |
| Category: Hematology/Oncology | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Pevonedistat-3001 PANTHER North and Latin American Investigator Meeting - All Day Beverages 4-20 | Takeda Pharmaceuticals U.S.A., Inc. | $38,014 | 17 |
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) | Eli Lilly and Company | $168.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 1,639 | 43,193 | $2.7M | $532,935 |
| 2022 | 53 | 1,958 | 63,607 | $4.2M | $961,851 |
| 2021 | 55 | 2,388 | 77,304 | $4.4M | $980,362 |
| 2020 | 49 | 2,214 | 69,992 | $3.6M | $768,510 |
Total Patients
8,199
Total Services
254,096
Medicare Billing
$3.2M
Procedure Codes
207
All Medicare Procedures & Services
207 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 4,290 | $631,680 | $187,111 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 165 | 441 | $128,772 | $58,475 | 45.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 35 | 38 | $152,000 | $46,073 | 30.3% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 14 | 1,330 | $332,760 | $44,591 | 13.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 1,860 | $128,220 | $33,847 | 26.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 101 | 200 | $133,200 | $19,762 | 14.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 8,050 | $169,050 | $19,078 | 11.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 11 | 1,100 | $80,900 | $18,466 | 22.8% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 12 | 180 | $158,220 | $16,018 | 10.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 35 | 163 | $11,410 | $11,417 | 100.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $26,397 | $10,035 | 38.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 27 | 6,370 | $57,330 | $8,725 | 15.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 47 | $185,086 | $6,408 | 3.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 88 | 399 | $40,698 | $4,700 | 11.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 52 | $11,284 | $4,494 | 39.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 68 | 92 | $27,140 | $4,300 | 15.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 40 | 43 | $6,045 | $4,295 | 71.1% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 14 | 29 | $28,594 | $3,846 | 13.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 56 | $11,144 | $3,114 | 27.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 33 | 61 | $19,764 | $2,953 | 14.9% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 95 | 146 | $8,760 | $2,783 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $6,660 | $2,218 | 33.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $6,000 | $2,009 | 33.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 96 | 178 | $16,020 | $1,882 | 11.7% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 71 | $9,727 | $1,658 | 17.0% |
About Dr. Sudhir Manda, MD
Dr. Sudhir Manda, MD is a Hematology & Oncology healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164630679.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sudhir Manda, MD has received a total of $50,979 in payments from pharmaceutical and medical device companies, with $1,743 received in 2024. These payments were reported across 557 transactions from 52 companies. The most common payment nature is "" ($38,182).
As a Medicare-enrolled provider, Manda has provided services to 8,199 Medicare beneficiaries, totaling 254,096 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 207 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Tucson, AZ
- Active Since 05/18/2007
- Last Updated 03/09/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1164630679
Products in Payments
- OPDIVO (Biological) $600.31
- KEYTRUDA (Biological) $571.13
- REBLOZYL (Biological) $338.20
- IBRANCE (Drug) $308.11
- Da Vinci Surgical System (Device) $203.81
- Lenvima (Drug) $182.45
- DARZALEX (Biological) $159.93
- KISQALI (Drug) $158.11
- VENCLEXTA (Drug) $157.63
- INLYTA (Drug) $148.64
- GILOTRIF (Drug) $142.19
- XGEVA (Biological) $137.74
- Fabhalta (Drug) $133.46
- ADCETRIS (Biological) $111.04
- SOLIRIS (Drug) $104.75
- Nerlynx (Drug) $102.75
- ORGOVYX (Drug) $101.48
- Epkinly (Drug) $100.61
- PROMACTA (Drug) $97.32
- XALKORI (Drug) $95.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tucson
Dr. Christopher Chen, Md, Mba, MD, MBA
Hematology & Oncology — Payments: $312,281
Hematology & Oncology $312,281
Dr. Rachna Shroff, Md, MD
Hematology & Oncology — Payments: $257,150
Hematology & Oncology $257,150
Alison Stopeck, Md, MD
Hematology & Oncology — Payments: $240,782
Hematology & Oncology $240,782
Michael Boxer, M.d, M.D
Hematology & Oncology — Payments: $86,711
Hematology & Oncology $86,711
Dr. Rachel Swart, M.d.,Ph.d, M.D.,PH.D
Hematology & Oncology — Payments: $69,563
Hematology & Oncology $69,563
Basel Shoua, M.d, M.D
Hematology & Oncology — Payments: $45,611
Hematology & Oncology $45,611